atai Life Sciences (ATAI)
(Delayed Data from NSDQ)
$4.17 USD
+0.07 (1.71%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $4.18 +0.01 (0.24%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ATAI 4.17 +0.07(1.71%)
Will ATAI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ATAI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATAI
atai Life Sciences (ATAI) Upgraded to Strong Buy: Here's Why
Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year?
ATAI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Medical Stocks Lagging atai Life Sciences (ATAI) This Year?
Are You Looking for a Top Momentum Pick? Why atai Life Sciences N.V. (ATAI) is a Great Choice
Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year?
Other News for ATAI
Oppenheimer Boosts Price Target for ATAI Life Sciences Due to Promising Prospects
Atai Life Sciences price target raised by $2 at Oppenheimer, here's why
Psychedelic stocks up after report on AbbVie-Gilgamesh deal talks
Psychedelic: Filament reports compassionate use approval for psilocybin
This IonQ Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday